子痫前期患者检测凝血、抗凝和纤溶实验室指标的价值分析

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (36 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察凝血、抗凝及纤溶指标在不同程度妊娠期高血压病患者中的水平变化及对母婴结局的影响。方法回顾性分析2017年8月～2018年8月在深圳市妇幼保健院分娩的130 例妊娠期高血压病孕产妇的临床资料，其中妊娠期高血压41 例，轻度子痫前期51 例，重度子痫前期38 例；另选取同期在深圳市妇幼保健院分娩的健康孕产妇40 例，分析其凝血酶原时间（PT）、活化部分凝血酶时间（APTT）、抗凝血酶-Ⅲ（AT-Ⅲ）、D-二聚体（D-D）、组织纤溶酶原激活物（t-PA）、纤溶酶原激活抑制物-1（PAI-1）、纤维蛋白原（FIB）、纤维蛋白原降解产物（FDP）水平在不同时期妊娠期高血压病中的水平变化，记录妊娠期高血压病孕产妇不良母婴结局（胎盘早剥、产后出血、胎儿生长受限、宫内窘迫、早产、死胎/死产）发生情况。结果妊娠期高血压病孕产妇的PT、APTT 均短于健康孕产妇，AT-Ⅲ指标水平低于健康孕产妇，D-D、t-PA、PAI-1、FIB、FDP 水平短高于健康孕产妇，差异有统计学意义（P＜0.05）。在妊娠期高血压病不同时期孕产妇中，重度子痫前期孕产妇的PT、APTT 均短于轻度子痫前期和妊娠期高血压孕产妇，AT-Ⅲ水平低于轻度子痫前期和妊娠期高血压孕产妇，D-D、PAI-1、FDP、FIB 水平均高于轻度子痫前期和妊娠期高血压孕产妇，差异有统计学意义（P＜0.05）。存在不良母婴结局孕产妇的AT-Ⅲ水平低于无不良结局孕产妇，PAI-1 水平高于无不良结局孕产妇，差异有统计学意义（P＜0.05）。结论妊娠期高血压病特别是子痫前期孕产妇血液呈异常高凝状态，早期动态检测凝血、抗凝、纤溶指标有助于预防不良母婴结局的发生。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	林兵英
	罗晓燕
	方周宾
	朱岩

关键词 ：凝血指标, 纤溶指标, 子痫前期, 母婴结局

Abstract：Objective To observe the changes of blood coagulation, anticoagulation and fibrinolysis indicators in patients with pregnancy-induced hypertension at different degrees and their effects on maternal and fetal outcomes.Methods A retrospective analysis of clinical data of 130 pregnant women with pregnancy-induced hypertension during the delivery from August 2017 to August 2018 in Shenzhen Maternal and Child Health Care Hospital was made, including 41 cases gestational hypertension, 51 cases mild preeclampsia, and 38 cases severe preeclampsia.Meanwhile,another 40 cases of healthy pregnant women who delivered in Shenzhen Maternal and Child Health Care Hospital were enrolled.The prothrombin time (PT), activated partial thrombin time (APTT), antithrombin-Ⅲ(AT-Ⅲ), D-dimer (DD), tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), fibrinogen (FIB), and fibrinogen degradation products (FDP) levels of gestational hypertension in different periods were analyzed.The occurrence of adverse maternal outcomes in pregnancy-induced hypertension women such as placental abruption, postpartum hemorrhage, fetal growth restriction, intrauterine distress, premature delivery, and stillbirth was recorded.Results The PT and APTT in pregnant women with gestational hypertension were shorter than those in healthy pregnant women, the level of AT-Ⅲwas lower than that in the healthy pregnant women, and the levels of D-D, t-PA, PAI-1, FIB and FDP were higher than those in the healthy pregnant women, with statistically significant differences (P＜0.05).In pregnant women at different stages of hypertensive gestation, the PT and APTT in severe preeclampsia were shorter than those in mild preeclampsia and gestational hypertension, the level of AT-Ⅲin severe preeclampsia was lower than that in mild preeclampsia and gestational hypertension, and the levels of D-D, PAI-1, FDP and FIB were higher than those in mild preeclampsia and gestational hypertension, with statistically significant differences (P＜0.05).The level of maternal AT-Ⅲin patients with adverse maternal and infant outcomes was lower than that without adverse maternal outcome, the level of PAI-1 was higher compared with that without adverse outcomes, with statistically significant differences (P＜0.05).Conclusion Women with pregnancy-induced hypertension, especially in preeclampsia, is abnormally hypercoagulable.Early detection of blood coagulation, anticoagulation and fibrinolysis can prevent the occurrence of adverse maternal and child outcomes.

Key words： Coagulation indicator Fibrinolysis indicator Preeclampsia Maternal and child outcomes

引用本文:

林兵英；罗晓燕；方周宾；朱岩. 子痫前期患者检测凝血、抗凝和纤溶实验室指标的价值分析[J]. 中国当代医药, 2019, 26(12): 26-29.
LIN Bing-yin； LUO Xiao-yan；FANG Zhou-bin；ZHU Yan. Value analysis of laboratory indicators for blood coagulation, anticoagulation and fibrinolysis in patients with preeclampsia. 中国当代医药, 2019, 26(12): 26-29.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2019/V26/I12/26

[1]	胡娟，余信强，叶枫.早发型子痫前期患者血小板参数、凝血指标及相关蛋白测定的临床意义[J].世界临床药物，2016，37（4）：250-253.
[2]	赵嵩，安莲英，彭丽霞，等.子痫前期患者应用低分子肝素钠辅助治疗对其凝血功能及肾功能的影响[J].疑难病杂志，2016，15（7）：716-719.
[3]	张锋，李晓丹，胡艳君，等.凝血、抗凝和纤溶实验室指标在子痫前期中的应用[J].中国妇幼保健，2016，31（6）：1160-1163.
[4]	杨孜，张为元.妊娠期高血压疾病诊治指南（2015）解读[J].中国实用妇科与产科杂志，2015，31（9）：836-841.
[5]	陈华干，李雪丽，杨兴兴，等.凝血指标检测在重度子痫前期的临床意义[J].血栓与止血学，2016，22（4）：479-480.
[6]	李杰锋，蒋龙元.子痫前期凝血功能异常及抗凝药在子痫前期中的应用[J].岭南急诊医学杂志，2018，23（1）：92-94.
[7]	李俊芳，郭小群.全麻复合硬膜外麻醉对子痫前期患者凝血功能指标的影响[J].医学临床研究，2018，（3）：507-509.
[8]	董方华，杜丹，何栩，等.子痫前期患者血浆miRNA 及相关凝血功能指标的相关性分析[J].广东医学，2016，37（16）：2434-2436.
[9]	蒋比芬，周斌.血小板参数、凝血指标、CRP 及PAPP-A 在早发型子痫前期患者中表达的意义[J].中外医疗，2018，37（30）：23-25.
[10]	王双，王志梅，杨佳佳，等.凝血功能指标、血小板参数与妊娠晚期子痫前期的关系研究[J].中国全科医学，2018，21（4）：444-448.
[11]	熊贤海，郑丹.重度子痫前期患者凝血功能及vWF 含量的变化和意义[J].江西医药，2016，51（10）：1031-1033.
[12]	贾佳，杨巧妮，赵子房，等.晚期妊娠合并重度子痫前期患者血栓弹力图特点分析[J].中国医科大学学报，2016，45（12）：1105-1109.
[13]	刘梦园，崔世红.早发型重度子痫前期合并胎儿生长受限易栓三项、凝血指标及母婴结局分析[J].实用妇科内分泌杂志（电子版），2017，4（29）：1-3.
[14]	李霞，曾洪伟，李波，等.子痫前期患者凝血指标及肿瘤坏死因子-α 与溶血、肝酶升高及血小板减少综合征的相关性研究[J].中国计划生育和妇产科，2017，9（6）：51-54.
[15]	胡艳君，李晓庆，郑加永，等.重度子痫前期患者凝血功能的变化及意义[J].中国现代医生，2018，56（17）：54-57.